The current invention relates to anti-HER2 monoclonal antibodies and chimeric antigen receptors comprising anti-HER2 antigen-binding domains. In particular, the disclosed antibodies are capable of inducing apoptosis in HER2-expressing cells. The current invention also relates to a pharmaceutical composition comprising said antibodies and its use thereof to treat cancer.